Dr. Lal PathLabs Limited
LALPATHLAB
Rangering i aksjer
#4525
Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health... Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health assessment services, operating both domestically in India and across international borders. The company manages a comprehensive network of laboratories dedicated to conducting pathological investigations across various specialized fields. These include biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, in addition to other general pathological and radiological studies. Beyond its core testing operations, Dr. Lal PathLabs also offers laboratory staff training, technical support, and full-scale lab management services. As of March 31, 2022, its widespread infrastructure included 277 clinical laboratories, notably a National Reference Lab located in Delhi and a Regional Reference Lab in Kolkata. This is further bolstered by 4,731 patient service centers and 10,599 sample collection points. Founded in 1949, Dr. Lal PathLabs Limited maintains its corporate base in Gurugram, India.
Aksjekurs
$20.35
Sist synkronisert: 2026-10-19
Markedsverdi
$3.40B
Endring (1 dag)
-0.86%
Endring (1 år)
13.63%
Land
IN
Handel Dr. Lal PathLabs Limited (LALPATHLAB)
Kategori
Healthcare
P/B-forhold for Dr. Lal PathLabs Limited (LALPATHLAB)
P/B-forhold per October 2026 TTM: 12.30
Ifølge Dr. Lal PathLabs Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 12.30. Ved slutten av 2024 hadde selskapet et P/B-forhold på 10.30.
P/B-historikk for Dr. Lal PathLabs Limited fra 2011 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 12.30 | 33.57% |
| 2025 | 9.21 | -10.56% |
| 2024 | 10.30 | 13.24% |
| 2023 | 9.09 | -36.47% |
| 2022 | 14.31 | -20.24% |
| 2021 | 17.95 | 60.49% |
| 2020 | 11.18 | 22.31% |
| 2019 | 9.14 | 1.33% |
| 2018 | 9.02 | -24.30% |
| 2017 | 11.92 | -20.38% |
| 2016 | 14.97 | 14.51% |
| 2015 | 13.07 | -55.61% |
| 2014 | 29.45 | -29.99% |
| 2013 | 42.07 | -28.44% |
| 2012 | 58.79 | -19.94% |
| 2011 | 73.44 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 4.7411 | -61.46% |
US
|
|
| 3.0143 | -75.50% |
US
|
|
| 31.051 | 152.42% |
US
|
|
| - | - |
CN
|
|
| 6.6641 | -45.83% |
US
|
